Amanda Copeland

In the U.S.

I joined Memorial Sloan Kettering in January 2013 after more than eight years as an Advanced Practice Nurse at MD Anderson Cancer Center in Houston. I began my career working with patients taking conventional lymphoma therapies, but I quickly realized that my true passion was clinical trials, working with novel therapies in lymphoma. I transitioned to a position as a research nurse, managing trials and helping patients follow various treatment protocols.

Now at Memorial Sloan Kettering, I work with the Chief of the Lymphoma Service, Anas Younes. I feel very fortunate to have been asked to join him here, and I am very excited about the achievements the service has made thus far and the opportunities that lie ahead. We have many promising therapies at MSK for lymphoma patients, in addition to the wonderful and dedicated research and clinical staff I am fortunate to work with. I am very excited to be a part of the development of these novel agents and to have the opportunity to work with patients receiving investigational treatments.

Languages Spoken

English

Licensures

Master of Science in Nursing (MSN), the University of Texas at Austin
Bachelor of Arts (BA), the University of Texas at Austin
Clinical Nurse Specialist (CNS), Adult Health
Registered Professional Nurse (RN)
Lymphoma
Clinical Trials

Publications

Copeland, A. and Younes, A. (2012). Current treatment strategies in Hodgkin lymphoma. Current Opinion in Oncology, 24, 466-474.

Copeland, A., et al. (2012). Phase I Study of Anti-CD19 Antibody-Drug Conjugate SAR3419 in Relapsed Lymphoma. Pan Pacific Lymphoma Conference (Abstract).

Copeland, A., et al. (2011). Results of a Phase I/II Study of the Combination of Panobinostat (LBH589) and Everolimus (RAD001) in Relapsed/Refractory Hodgkin and Non-Hodgkin Lymphoma. Pan Pacific Lymphoma Conference (Abstract).

Copeland, A. Buglio, D. and Younes, A. (2010). Histone deacetylase inhibitors in lymphoma.Current Opinion in Oncology, 22, 431-436.

Copeland, A. and Younes, A. (2010). Brentuximab vedotin. Drugs of the future, 35, 797-.

Copeland, A.,et al. (2009). Final Report of a Phase-II Study of Rituximab Plus ABVD for Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma.: Results of Long Follow up and Comparison to Institutional Historical Data. Blood (ASH Annual Meeting Abstracts);114: 1680.

Copeland, A., et al. (2009). Event-free survival (EFS) improved in patients with classical Hodgkin’s lymphoma given Rituximab+ABVD: Final. Pan Pacific Lymphoma Conference (Abstract).

Wedgwood, A., et al., (2007) Rituximab + ABVD Improves Event-Free Survival (EFS) in Patients with Classical Hodgkin Lymphoma in All International Prognostic Score (IPS) Groups and in Patients Who Have PET Positive Disease after 2–3 Cycles of Therapy. ASH Annual Meeting Abstracts. 110, 215-.

Wedgwood, A, et al., (2005). The lymphomas: Molecular pathways and novel therapeutic targets.Current Hematology Reports, 4, 324-334.

Wedgwood, A. and Younes, A. (2006). Targeting lymphoma cells and their microenvironment with novel antibodies. Clinical Lymphoma Myeloma, 7, S33-40.

Wedgwood, A. and Younes, A. (2009). Targeted therapy in lymphoma. In, Targeted therapy in cancer.

Wedgwood, A, et al. (2006). CD20+ nodal marginal zone B-cell lymphoma with CD20- recurrence as an intracranieal dural-based mass.Leukemia Lymphoma, 47, 2253-6.